Protagonist Therapeutics FY 2024: net income $275.2M; diluted EPS $4.23
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001558370-25-001317
- Document
- 10-K
- Exhibit 4.2
- Warrants or notes
- Exhibit 10.28
- Material contract
Key figures from this report
These are the numbers Protagonist Therapeutics reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Net income$275.2MAgainst −$79.0M in FY 202310-K income statement, on EDGAR
- Diluted EPS$4.23Against −$1.39 in FY 202310-K income statement, on EDGAR
- Cash and cash equivalents$97.2M−48% from $186.7M in FY 2023Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations$184.2MAgainst −$70.2M in FY 202310-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Prestige Consumer Healthcare PBH public float $3.0B, Sep 30, 2025
- Viking Therapeutics VKTX public float $3.0B, Jun 30, 2025
- Catalyst Pharmaceuticals CPRX public float $2.5B, Jun 30, 2025
- Cytokinetics CYTK public float $2.5B, Jun 30, 2025
- TG Therapeutics TGTX public float $2.5B, Jun 30, 2025